SUMMARY Skin reactivity to dinitrochlorobenzene (DNCB) and levels of circulating T-lymphocytes were measured in 15 patients with ulcerative colitis, 15 patients with Crohn's disease, and 12 normal control subjects. Diminished reactivity to DNCB was demonstrated in 87 % of patients with Crohn's disease (p < 0 001) and in 53 % with ulcerative colitis (p < 0 02), as compared with only 8-5 % of controls; anergy was more frequent in Crohn's disease than in ulcerative colitis (p < 0 05
have indicated impaired lymphocyte responsiveness and diminished proportions and absolute counts of circulating T-cells in both Crohn's disease and ulcerative colitis (Sachar et al., 1973; Sachar et al., 1976) . These differing conclusions prompted us further to evaluate cellular immunity in patients with Crohn's disease and ulcerative colitis by measuring both cutaneous reactivity to dinitrochlorobenzene (DNCB) and levels of circulating T-lymphocytes.
Methods

PATIENTS
We studied 15 patients with ulcerative colitis (UC) and 15 with Crohn's disease (CD) . The duration of illness ranged from less than one year to more than 30 years. Two of the patients with ulcerative colitis had disease limited to the rectum alone, two to the rectum and sigmoid colon, and 10 to the left colon; one patient with universal colitis had had a total colectomy several years before the study. The Crohn's disease group consisted of seven patients with disease limited to distal ileum, five with ileocolitis, and three with only colonic disease. Crohn's colitis was distinguished from ulcerative colitis by 911 the criteria of Lockhart-Mummery and Morson (1960) , as outlined in our previous studies (Sachar et al., 1973; Greenstein et al., 1975) .
Disease activity was classified as absent, moderate, or severe. In patients with Crohn's disease, 'absent' referred to those clinically well after bowel resection with no iadiographic or proctoscopic evidence of disease; 'moderate' included those with radiographic and/or proctoscopic evidence of disease but in whom symptoms of abdominal pain and diarrhoea were minimal and fever, weight loss, abscess or fistula absent; 'severe' denoted those patients who had radiographic and/or proctoscopic evidence of disease with severe abdominal pain, diarrhoea, fever, weight loss, abscess, or fistula. In patients with ulcerative colitis, 'absent' disease meant previoustotal colectomy with a normally functioning ileostomy; 'moderate' included those patients with radiographic and/or proctoscopic evidence of disease but with minimal diarrhoea or rectal bleeding; 'severe', those with severe diarrhoea, pain, and rectal bleeding in addition to radiographic and/or proctoscopic evidence of disease. According to these criteria, the Crohn's disease group included three with absent, nine moderate, and three severe disease; and those with ulcerative colitis comprised one with absent, eight moderate, and six severe disease. Most patients were taking salicylazosulphapyridine at the time of study but had not received ACTH or corticosteroids nor undergone any surgery during the preceding month. None had received immunosuppressive therapy.
The normal control group (NC) consisted of 12 subjects who were all previously healthy with no apparent disease at the time of study. All groups were of similar age and sex distribution.
Before study, the research nature and possible adverse reactions of the DNCB skin test were fully discussed with the patients, who all gave informed consent. DNCB 
TESTING
The method for DNCB testing was as described by Catalona et al. (1972) . A sensitising dose of 2000 jug DNCB in 0-1 ml acetone was applied evenly over a circular area 2 cm in diameter on the volar surface of the forearm. The solvent was allowed to evaporate and the area covered with a dry dressing for 24 hours. A challenge dose of 100 ,ug DNCB was applied 12 to 14 days later. A positive response consisted of induration and erythema at the test site 10 to 12 days after primary sensitisation or two to three days after secondary challenge.
BLOOD LYMPHOCYTE LEVELS
The peripheral lymphocyte count was calculated from total white blood count and differential smear. Lymphocytes were separated from heparinised peripheral venous blood by Ficoll-Hypaque sedimentation (Boyum, 1967) , and washed thrice in minimal Eagle's medium containing 5% fetal calf serum. The number of T-lymphocytes was determined by counting the 'E-rosettes' formed with washed fresh unsensitised sheep erythrocytes using the method of Bentwich et al. (1973) . The present Tcell studies represent a different series of measurements from those we have previously reported (Ramachandar et al., 1974; Sachar et al., 1976 Significant difference from controls: * P < 0-001, t P < 0-02. (Figure) . Although DNCB-anergy and T-cell depression followed similar patterns (occurrence in CD < UC < NC), there was no correlation between impaired DNCB responses and low T-lymphocyte levels (defined as < 1100 per cu mm), within each patient group (Table 4) 
Discussion
The development of delayed cutaneous reactions to topically applied dinitrochlorobenzene has come to be accepted as evidence for intact cell-mediated immune function (Aisenberg, 1962) . The increased frequency of anergy to DNCB which we have found in patients both with UC and with CD suggests some impairment of cell-mediated immunity in both of these diseases. This is in agreement with our previous findings of impaired lymphocyte responsiveness to phytohaemagglutinin (Sachar et al., 1973) and decreased proportions and absolute counts of circulating T-lymphocytes . A number of previous studies in patients with Crohn's disease have pointed to a moderate decrease in one or more indices of cellular immune function. The present finding of impaired DNCB responses, for example, agrees closely with the earlier data of Jones et al. (1969) . Similarly, impaired lymphocyte response to phytohaemagglutinin has been reported in several studies of CD (Walker and Greaves, 1969; Brown et al., 1970; McHattie et al., 1971; Parent et al., 1971; Asquith et al., 1973) , as have decreased levels of circulating T-lymphocytes (Strickland et al., 1974) and impaired cutaneous responsiveness to a broad spectrum of antigens (Meuwissen et al., 1975 (Bird and Britton, 1974; Bolton et al., 1974) were not carried out with a PHA dose-response curve and may not have been sufficiently sensitive. Bolton et al. (1974) have also reported 'normal' DNCB-reactivity in both CD and UC, but the DNCB-anergy rate in their control group was considerably higher than that in most other studies, which may have vitiated the significance of the high incidence of anergy observed in their patient groups.
Our present and past observations of impaired cellular immunity in UC contrast with the conclusions of some other previous reports. Some possible technical reasons for apparent lack of impaired PHA-responsiveness in other studies (Hinz et al., 1967; Stefani and Fink, 1967; Parent et al., 1971; Aas et al., 1972; Asquith et al., 1973; Bolton et al., 1974) have been discussed by us previously (Sachar et al., 1973; Sachar and Taub, 1975) . Other claims of normal cellular immunity in ulcerative colitis have been based upon results of conventional skin testing with mumps, coccidioidin, and trichophyton (Binder et al., 1966) as well as with tuberculin (Bolton et al., 1974) . The discrepancy between these conventional skin tests and DNCB responses suggests that in inflammatory bowel disease there may be a defect in primary sensitisation to new antigens as opposed to the recall of sensitivities acquired before the onset of disease.
The functional and anatomical site and pathogenetic significance of the defect in cellular immunity seen in both ulcerative colitis and Crohn's disease remain unknown. It is possible that, in some cases, severe illness, malnutrition, or chronic intestinal transudation or sequestration of lymphocytes might contribute to defective cellular immunity. It appears unlikely, however, that these are the principal causative factors, since the impairments observed in the present and previous studies (Jones et al., 1969; Sachar et al., 1973; Strickland et (Tables 2 and 3) or whose peripheral T-cell counts were normal (Table  4) . It would now be important, therefore, to determine if the defect represents a secondary manifestation of some other unrecognised facet of inflammatory bowel disease, or a primary pathogenetic factor in susceptibility, or some independent genetic 'marker' of disease predisposition. Studies of relatives of patients with inflammatory bowel disease and of long-term postcolectomy ulcerative colitis patients are now under way in order to shed additional light on this question. 
